By Alain J. Gilbert, Co-Chair, Bionest Partners The U.S. Presidential election is over. No matter how you personally feel about the outcome, the fact of Donald Trump’s election is likely to be positive for the healthcare industry and biopharma. The reason: the issue of new drug pricing is not going to be a top...
The theme of patient centricity and care that we discussed at this year’s ASCO continued this autumn at ESMO 2016. The tagline of the conference was ‘From disease treatment to patient care,’ which according to the organizers, “intended to capture and integrate clinical research with patient needs, and reinforces our commitment to bring the best...